Therapeutics Articles
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
Specialists at India’s Sir Ganga Ram Hospital conducted a double-blinded, randomized controlled study to examine the impact of high oncotic pressure priming by the addition of 20 percent human albumin prior to the initiation of CPB
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.
This trial suggests that plasma exchange with albumin replacement could slow cognitive and functional decline in Alzheimer’s disease, although further studies are warranted.
The investigators concluded lower, more frequent dosing does not further improve the efficacy of IVIG in stable IVIG-dependent CIDP patients, or result in fewer side effects.
Titrating the IgG trough level up to 960 mg/dL progressively reduces the infection rate in PI patients, but there is less incremental benefit above this trough level.
More than two years after receiving Spark Therapeutics’ investigational adeno-associated virus (AAV)-mediated gene therapy (SPK-8011), five adult subjects with hemophilia A exhibited stable factor VIII (FVIII) expression, with no evidence of FVIII inhibitors or a cellular immune response.
Investigators conducted a retrospective review of 38 cases treated at Taipei Veterans General Hospital between January 2007 and December 2018 to determine whether more aggressive albumin supplementation can benefit major burn patients with persistent hypoalbuminemia.
Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.
The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.